Cancer therapeutic targeting using mutant–p53-specific siRNAs

Abstract excerpt

Mutations in Tp53 compromise therapeutic response, due either to the dominant-negative effect over the functional wild-type allele; or as a result of the survival advantage conferred by mutant p53 to which cancer cells become addicted. Thus, targeting mutant p53 represents an effective therapeutic strategy to treat over half of all cancers. We have therefore generated a series of small-interfering-RNAs, capable...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced biosensing and bioanalysis techniques
• Share to Cancer-related Molecular Pathways
• Share to RNA Interference and Gene Delivery